AES-135

CAT: 0804-HY-114483-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-114483-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
AES-135, a hydroxamic acid-based pan-HDAC inhibitor, prolongs survival in an orthotopic mouse model of pancreatic cancer. AES-135 inhibits HDAC3, HDAC6, HDAC8, and HDAC11 with IC50s ranging from 190-1100 nM[1].
CAS Number
[2361659-61-0]
UNSPSC
12352005
Target
HDAC
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/AES-135.html
Concentration
10mM
Purity
98.21
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC(C)(C)C1=CC=C(CN(C(CN(CC2=C(F)C(F)=C(F)C(F)=C2F)S(=O)(C3=CC=C(F)C=C3)=O)=O)C4=CC=C(C(NO)=O)C=C4)C=C1
Molecular Formula
C33H29F6N3O5S
Molecular Weight
693.66
References & Citations
[1]Shouksmith AE, et al. Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer. J Med Chem. 2019 Mar 14;62 (5) :2651-2665.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HDAC11; HDAC3; HDAC6; HDAC8

Related Products

CatalogName
HY-138831-01AES-350
HY-168627EGFR-IN-135
HY-118329S 135
HY-111416WY-135
HY-111055-01BIP-135
HY-164463BMI-135
HY-10869-01OL-135
HY-178051Antifungal agent 135
HY-145953-01VY-3-135
HY-155543Anticancer agent 135

Alternative Products

CatalogName
M24072-01AES-135
A19087-5AES-135 5mg
A19087-100AES-135 100mg
A19087-10AES-135 10mg
A19087-25AES-135 25mg
A19087-1AES-135 1mg
A19087-50AES-135 50mg
A19087-10mM-DAES-135 10mM * 1mL in DMSO
305116-01AES
469889AES (AES-1, AES-2, ESP1, GRG, GRG5, TLE5)

Popular Products